S. Adam

发表

JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function

C. Scholtysek, G. Schett, A. Kleyer, 2020, Science Translational Medicine.

Full Length Interleukin 33 Aggravates Radiation-Induced Skin Reaction

S. Wirtz, G. Schett, I. McInnes, 2017, Front. Immunol..

Expression, regulation and clinical significance of bone morphogenetic protein 6 in esophageal squamous‐cell carcinoma

H. Gabbert, M. Sarbia, J. Clement, 1999, International journal of cancer.

The soluble CD83 protein prevents bone destruction by inhibiting the formation of osteoclasts and inducing resolution of inflammation in arthritis

G. Schett, A. Steinkasserer, T. Bäuerle, 2022, Frontiers in Immunology.

Prospects of JAK Inhibition in the Framework of Bone Loss

G. Schett, S. Frey, S. Adam, 2021, Journal of Cellular Immunology.

The human sialic acid-binding immunoglobulin-like lectin Siglec-9 and its murine homolog Siglec-E control osteoclast activity and bone resorption.

G. Schett, L. Nitschke, M. Hahn, 2020, Bone.

Metabolic reprogramming of osteoclasts represents a therapeutic target during the treatment of osteoporosis

D. Mougiakakos, U. Sonnewald, C. Scholtysek, 2020, Scientific Reports.

Structural insights into heme binding to IL-36α proinflammatory cytokine

J. Popp, S. Heinemann, U. Neugebauer, 2019, Scientific Reports.